Authors

Ayala Tamir, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Ushma Jag, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Sreeja Sarojini, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Craig Schindewolf, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Takemi Tanaka, Department of Nanomedicine and Biomedical Engineering, University of Texas Health Science Center at Houston, Houston, TX; Department of Biomedical Engineering, University of Texas Austin, Austin, TX; Department of Pharmaceutical Sciences, Thomas Jefferson University, Philadelphia, PAFollow
Rajendra Gharbaran, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Hiren Patel, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Anil Sood, Departments of Gynecologic Oncology and Cancer Biology, MD Anderson Cancer Center, University of Texas
Wei Hu, Departments of Gynecologic Oncology and Cancer Biology, MD Anderson Cancer Center, University of Texas
Ruzeen Patwa, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Patrick Blake, Sophic Systems Alliance, Inc
Polina Chirina, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Jin Oh Jeong, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Heejin Lim, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Andre Goy, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
Andrew Pecora, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center
K Stephen Suh, The Genomics and Biomarkers Program, The John Theurer Cancer Center, Hackensack University Medical Center

Document Type

Article

Publication Date

12-5-2014

Comments

This article has been peer reviewed. It was published in: Journal of ovarian research.

Volume 7, 2014, Page 109.

The published version is available at DOI: 10.1186/s13048-014-0109-z

Copyright © Tamir et al.; licensee BioMed Central Ltd. 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Abstract

BACKGROUND: Early detection of ovarian cancer remains a challenge due to widespread metastases and a lack of biomarkers for early-stage disease. This study was conducted to identify relevant biomarkers for both laparoscopic and serum diagnostics in ovarian cancer.

METHODS: Bioinformatics analysis and expression screening in ovarian cancer cell lines were employed. Selected biomarkers were further validated in bio-specimens of diverse cancer types and ovarian cancer subtypes. For non-invasive detection, biomarker proteins were evaluated in serum samples from ovarian cancer patients.

RESULTS: Two kallikrein (KLK) serine protease family members (KLK6 and KLK7) were found to be significantly overexpressed relative to normal controls in most of the ovarian cancer cell lines examined. Overexpression of KLK6 and KLK7 mRNA was specific to ovarian cancer, in particular to serous and papillary serous subtypes. In situ hybridization and histopathology further confirmed significantly elevated levels of KLK6 and KLK7 mRNA and proteins in tissue epithelium and a lack of expression in neighboring stroma. Lastly, KLK6 and KLK7 protein levels were significantly elevated in serum samples from serous and papillary serous subtypes in the early stages of ovarian cancer, and therefore could potentially decrease the high "false negative" rates found in the same patients with the common ovarian cancer biomarkers human epididymis protein 4 (HE4) and cancer antigen 125 (CA-125).

CONCLUSION: KLK6 and KLK7 mRNA and protein overexpression is directly associated with early-stage ovarian tumors and can be measured in patient tissue and serum samples. Assays based on KLK6 and KLK7 expression may provide specific and sensitive information for early detection of ovarian cancer.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

COinS